Overview

A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis

Status:
Completed

Trial end date:
2019-03-21

Target enrollment:

Participant gender:

Summary

The primary objective is to demonstrate added benefit of brodalumab versus a selected systemic comparator in treatment of moderate to severe plaque psoriasis in Germany in subjects who have not previously received systemic treatment for psoriasis. > Fumaric acid esters have been selected as the comparator because it is an established systemic treatment of psoriasis in Germany.>

Phase:

Phase 4

Details

Lead Sponsor:

LEO Pharma

Treatments:

Antibodies, Monoclonal
Brodalumab
Dimethyl Fumarate